Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma

Kim A. Selting, Gregory K. Ogilvie, Daniel L. Gustafson, Michael E. Long, Susan E. Lana, Judy A. Walton, Rodney A. Hansen, A. Simon Turner, Irene Laible, Martin J. Fettman

Research output: Contribution to journalArticle

Abstract

Objective - To determine the effect of dietary n-3 fatty acids on the pharmacokinetics of doxorubicin in dogs with lymphoma. Animals - 23 dogs with lymphoma in stages IIIa, IVa, and Va. Procedure - Dogs receiving doxorubicin chemotherapy were randomly allocated to receive food with a high (test group) or low (control group) content of n-3 fatty acids. Serum doxorubicin and doxorubicinol concentrations were measured via high-performance liquid chromatography before and 6 to 9 weeks after initiation of the diets. Lymph node concentrations of doxorubicin were assessed 6 hours after the initial treatment. Dogs' body composition was assessed by means of dual-energy x-ray absorptiometry scans. Results - No significant differences in doxorubicin pharmacokinetics were detected between treatment groups. Significant differences existed between the first and second sampling times among all dogs for area under the curve, maximum serum concentration, and clearance. Differences in body composition did not affect measured pharmacokinetic variables. The terminal elimination half-life was longer in dogs in which a long-term remission was achieved than in dogs that did not have remission. Conclusions and clinical relevance - Dietary supplementation of n-3 fatty acids is common in veterinary patients with neoplasia, but supplementation did not affect doxorubicin pharmacokinetics in this population of dogs. Explanations for the beneficial effects of n-3 fatty acids other than alterations in the pharmacokinetics of chemotherapy drugs should be investigated. Dogs may metabolize drugs differently prior to remission of lymphoma than when in remission. The pharmacokinetics of doxorubicin at the time of the first administration may predict response to treatment.

Original languageEnglish (US)
Pages (from-to)145-151
Number of pages7
JournalAmerican journal of veterinary research
Volume67
Issue number1
DOIs
StatePublished - Jan 1 2006
Externally publishedYes

ASJC Scopus subject areas

  • veterinary(all)

Fingerprint Dive into the research topics of 'Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Selting, K. A., Ogilvie, G. K., Gustafson, D. L., Long, M. E., Lana, S. E., Walton, J. A., Hansen, R. A., Turner, A. S., Laible, I., & Fettman, M. J. (2006). Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma. American journal of veterinary research, 67(1), 145-151. https://doi.org/10.2460/ajvr.67.1.145